Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05797168 · ClinicalTrials.gov registry record · Phase 1

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
506
Enrollment target
20
Study locations

NCT05797168 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 506 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05797168, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
506 participants
Enrollment target
20
Study locations

Study Summary

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Conditions Studied

Ovarian Cancer Endometrial Cancer Lung Adenocarcinoma

Interventions

  • DRUG AZD5335
  • DRUG Saruparib (AZD5305)
  • DRUG Bevacizumab
  • DRUG Carboplatin
  • DRUG AZD9574

Study Locations (20)

California

  • Research Site - Duarte
  • Research Site - Irvine
  • Research Site - La Jolla

Rhode Island

  • Research Site - Providence
  • Research Site - Providence

Other

  • Research Site - Liverpool
  • Research Site - Melbourne

Ontario

  • Research Site - London
  • Research Site - Toronto

Quebec

  • Research Site - Montreal
  • Research Site - Montreal

Colorado

  • Research Site - Aurora

Kentucky

  • Research Site - Louisville

Massachusetts

  • Research Site - Boston

Trial Details

FieldValue
Enrollment Target 506 participants
Start Date 2023-06-05
Est. Completion 2028-01-06
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05797168

The ClinicalTrials.gov registry entry for NCT05797168 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 506 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (30% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which AZD5335 is the first listed.

NCT05797168 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Rhode Island, Other.

Frequently Asked Questions

What is clinical trial NCT05797168 about?

NCT05797168 is a clinical study titled "Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors". This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

What is the current status of trial NCT05797168?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 506 participants. The study started on 2023-06-05. Estimated completion is 2028-01-06.

What conditions does trial NCT05797168 study?

This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Lung Adenocarcinoma.

What interventions are being tested in trial NCT05797168?

The interventions under investigation include: AZD5335 (DRUG), Saruparib (AZD5305) (DRUG), Bevacizumab (DRUG), Carboplatin (DRUG), AZD9574 (DRUG).

Who is sponsoring clinical trial NCT05797168?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05797168 being conducted?

This trial has 20 study locations across California, Colorado, Kentucky, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Endometrial Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.